BRPI0615223A2 - inibidores das serina proteases - Google Patents
inibidores das serina proteasesInfo
- Publication number
- BRPI0615223A2 BRPI0615223A2 BRPI0615223-6A BRPI0615223A BRPI0615223A2 BR PI0615223 A2 BRPI0615223 A2 BR PI0615223A2 BR PI0615223 A BRPI0615223 A BR PI0615223A BR PI0615223 A2 BRPI0615223 A2 BR PI0615223A2
- Authority
- BR
- Brazil
- Prior art keywords
- serine protease
- protease inhibitors
- activity
- hepatitis
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
INIBIDORES DAS SERINA PROTEASES. A presente invenção se refere aos compostos de fórmula (1); ou um sal farmaceuticamente aceitável ou misturas suas que inibem a atividade da serina protease, particularmente a atividade da N93-NS4A protease do vírus da hepatite C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71153005P | 2005-08-26 | 2005-08-26 | |
PCT/US2006/033770 WO2007025307A2 (en) | 2005-08-26 | 2006-08-28 | Inhibitors of serine proteases |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0615223A2 true BRPI0615223A2 (pt) | 2009-07-14 |
Family
ID=37684363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0615223-6A BRPI0615223A2 (pt) | 2005-08-26 | 2006-08-28 | inibidores das serina proteases |
Country Status (21)
Country | Link |
---|---|
US (2) | US7985762B2 (pt) |
EP (3) | EP2364984A1 (pt) |
JP (1) | JP5394063B2 (pt) |
KR (1) | KR20080041715A (pt) |
CN (1) | CN101316852A (pt) |
AR (1) | AR055395A1 (pt) |
AT (1) | ATE530554T1 (pt) |
AU (1) | AU2006282771B2 (pt) |
BR (1) | BRPI0615223A2 (pt) |
CA (1) | CA2620621A1 (pt) |
EA (1) | EA200800670A1 (pt) |
EC (1) | ECSP088258A (pt) |
ES (1) | ES2374943T3 (pt) |
GE (1) | GEP20115280B (pt) |
IL (1) | IL189668A0 (pt) |
MX (1) | MX2008002606A (pt) |
NO (1) | NO20081467L (pt) |
NZ (1) | NZ566197A (pt) |
TW (1) | TW200730533A (pt) |
WO (1) | WO2007025307A2 (pt) |
ZA (1) | ZA200801793B (pt) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04023B1 (et) * | 1996-10-18 | 2003-04-15 | Vertex Pharmaceuticals Incorporated | Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid |
EP1268519B1 (en) * | 2000-04-03 | 2005-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EP1613620A1 (en) * | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
NZ544789A (en) * | 2003-07-18 | 2010-01-29 | Vertex Pharma | Dithia-azaspiro-nonane and decane derivatives as inhibitors of serine proteases |
UY28500A1 (es) * | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
TW200526686A (en) * | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
RU2006115558A (ru) * | 2003-10-10 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
PT1677827E (pt) * | 2003-10-27 | 2009-03-13 | Vertex Pharma | Associações para o tratamento do vhc |
US7683033B2 (en) * | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
JP5249028B2 (ja) | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7964624B1 (en) * | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
WO2007098270A2 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same |
CA2646229A1 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
MX2008013119A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores de hcv/vih y sus usos. |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2007290535A1 (en) * | 2006-08-28 | 2008-03-06 | Vertex Pharmaceuticals Incorporated | Method for identifying protease inhibitors |
CA2664247A1 (en) * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2125113A2 (en) * | 2007-02-26 | 2009-12-02 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of hcv replication |
CN101903392A (zh) * | 2007-02-27 | 2010-12-01 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶的抑制剂 |
JP2010519330A (ja) | 2007-02-27 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶体およびそれを含む医薬組成物 |
FR2914920B1 (fr) * | 2007-04-11 | 2011-09-09 | Clariant Specialty Fine Chem F | Procede de deacetalisation d'alpha-aminoacetals. |
EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
AR066528A1 (es) * | 2007-05-10 | 2009-08-26 | Array Biopharma Inc | Peptidos inhibidores de la replicacion del virus de la hepatitis c |
UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
EP2100881A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Pyrimidyl- or pyridinylaminobenzoic acid derivatives |
CN101835774B (zh) | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | 共晶体和包含该共晶体的药物组合物 |
AR068756A1 (es) | 2007-10-10 | 2009-12-02 | Novartis Ag | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c |
WO2009053828A2 (en) * | 2007-10-22 | 2009-04-30 | Enanta Pharmaceuticals, Inc. | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
RU2490272C2 (ru) | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
CN102015652A (zh) | 2008-03-20 | 2011-04-13 | 益安药业 | 作为丙型肝炎病毒抑制剂的氟化大环化合物 |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2012505897A (ja) * | 2008-10-15 | 2012-03-08 | インターミューン・インコーポレーテッド | 治療用抗ウイルス性ペプチド |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2210615A1 (en) * | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US20130040978A1 (en) * | 2010-05-18 | 2013-02-14 | Joseph L. Duffy | Spiro isoxazoline compounds as sstr5 antagonists |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
PE20140039A1 (es) | 2010-12-30 | 2014-03-01 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN103304571B (zh) * | 2012-03-06 | 2018-02-16 | 凯惠科技发展(上海)有限公司 | 螺环化合物、其制备方法、中间体、药物组合物和应用 |
TW201408669A (zh) * | 2012-08-08 | 2014-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
ES2613766T3 (es) | 2012-10-19 | 2017-05-25 | Bristol-Myers Squibb Company | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
FR3000064A1 (fr) * | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
EP2883876A1 (en) | 2013-12-16 | 2015-06-17 | Actelion Pharmaceuticals Ltd. | Stereoselective synthesis of substituted pyrrolidines |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
WO2016144654A1 (en) | 2015-03-09 | 2016-09-15 | Washington University | Inhibitors of growth factor activation enzymes |
KR102096349B1 (ko) | 2015-07-31 | 2020-04-02 | 화이자 인코포레이티드 | Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체 및 1,1,1-트리플루오로-4-히드록시부탄-2-일 카르바메이트 유도체 |
WO2017156071A1 (en) | 2016-03-09 | 2017-09-14 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
WO2017222917A1 (en) * | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Aliphatic prolinamide derivatives |
US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
CN110023304A (zh) | 2016-09-28 | 2019-07-16 | 布莱德治疗公司 | 钙蛋白酶调节剂及其治疗用途 |
CA3050625C (en) | 2017-01-20 | 2021-07-20 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
AU2018208848A1 (en) | 2017-01-23 | 2019-07-18 | Pfizer Inc., | Heterocyclic spiro compounds as MAGL inhibitors |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
CN107954990A (zh) * | 2017-11-14 | 2018-04-24 | 安徽诺全药业有限公司 | 一种雷迪帕维的制备方法 |
CA3095164A1 (en) * | 2018-03-28 | 2019-10-03 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
Family Cites Families (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US472484A (en) * | 1892-04-05 | Pneumatic tire | ||
US633770A (en) | 1898-10-15 | 1899-09-26 | Diven Brothers & Company | Rotary plow. |
US3025516A (en) * | 1952-11-03 | 1962-03-13 | Stewart Warner Corp | Frequency control system for radio identification apparatus |
DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
DE3211676A1 (de) | 1982-03-30 | 1983-10-06 | Hoechst Ag | Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung |
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5496927A (en) * | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
DE3683541D1 (de) | 1985-06-07 | 1992-03-05 | Ici America Inc | Selektionierte difluorverbindungen. |
US5231084A (en) * | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
US5736520A (en) * | 1988-10-07 | 1998-04-07 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
DE4019586A1 (de) * | 1990-06-20 | 1992-01-02 | Bosch Gmbh Robert | Kraftstoffeinspritzsystem fuer brennkraftmaschinen |
US5371072A (en) | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
EP0604182B1 (en) * | 1992-12-22 | 2000-10-11 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of Aids |
DE69332616T2 (de) | 1992-12-29 | 2003-11-06 | Abbott Lab | Hemmer der retroviralen Protease |
US5384410A (en) * | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
US5656600A (en) | 1993-03-25 | 1997-08-12 | Corvas International, Inc. | α-ketoamide derivatives as inhibitors of thrombosis |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
IL113196A0 (en) | 1994-03-31 | 1995-06-29 | Bristol Myers Squibb Co | Imidazole derivatives and pharmaceutical compositions containing the same |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5861267A (en) * | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
EP1019410A1 (en) * | 1995-11-23 | 2000-07-19 | MERCK SHARP & DOHME LTD. | Spiro-piperidine derivatives and their use as tachykinin antagonists |
US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
ZA972195B (en) * | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
CN1116288C (zh) * | 1996-04-23 | 2003-07-30 | 沃泰克斯药物股份有限公司 | 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物 |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
WO1997043310A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US6153579A (en) | 1996-09-12 | 2000-11-28 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
AU723414B2 (en) * | 1996-09-25 | 2000-08-24 | Merck Sharp & Dohme Limited | Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists |
DE69725023T2 (de) * | 1996-10-08 | 2004-08-05 | Colorado State University Research Foundation, Fort Collins | Katalytische asymmetrische epoxidierung |
EE04023B1 (et) * | 1996-10-18 | 2003-04-15 | Vertex Pharmaceuticals Incorporated | Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
DE19648011A1 (de) * | 1996-11-20 | 1998-05-28 | Bayer Ag | Cyclische Imine |
AU6701598A (en) * | 1997-03-14 | 1998-09-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
GB9708484D0 (en) * | 1997-04-25 | 1997-06-18 | Merck Sharp & Dohme | Therapeutic agents |
GB9711114D0 (en) * | 1997-05-29 | 1997-07-23 | Merck Sharp & Dohme | Therapeutic agents |
HUP0004853A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
HUP0100100A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use |
US6183121B1 (en) * | 1997-08-14 | 2001-02-06 | Vertex Pharmaceuticals Inc. | Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets |
US20040058982A1 (en) * | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
WO1999028482A2 (en) * | 1997-11-28 | 1999-06-10 | Schering Corporation | Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
EP1066247B1 (en) | 1998-03-31 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US6251583B1 (en) * | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
GB9812523D0 (en) * | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (de) * | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
US6117639A (en) | 1998-08-31 | 2000-09-12 | Vertex Pharmaceuticals Incorporated | Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity |
US6025516A (en) | 1998-10-14 | 2000-02-15 | Chiragene, Inc. | Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
ATE400251T1 (de) * | 1999-02-09 | 2008-07-15 | Pfizer Prod Inc | Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit |
US20020042046A1 (en) * | 1999-02-25 | 2002-04-11 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
SK13332001A3 (sk) | 1999-03-19 | 2002-02-05 | Vertex Pharmaceuticals Incorporated | Inhibítory IMPDH enzýmu a ich použitie |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
AU6371900A (en) | 1999-07-26 | 2001-02-13 | Du Pont Pharmaceuticals Company | Lactam inhibitors of hepatitis c virus ns3 protease |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
US20020183249A1 (en) | 1999-08-31 | 2002-12-05 | Taylor Neil R. | Method of identifying inhibitors of CDC25 |
GB9925955D0 (en) | 1999-11-02 | 1999-12-29 | Angeletti P Ist Richerche Bio | Hcv n33 protease inhibitors |
AU2055301A (en) | 1999-12-03 | 2001-06-12 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease |
US6624290B2 (en) | 2000-02-08 | 2003-09-23 | Schering Corporation | Azapeptides useful in the treatment of Hepatitis C |
JP2003525294A (ja) | 2000-02-29 | 2003-08-26 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | C型肝炎ウイルスns3プロテアーゼの阻害剤 |
EP1268519B1 (en) | 2000-04-03 | 2005-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
CN1441806A (zh) * | 2000-04-05 | 2003-09-10 | 先灵公司 | 包含n-环p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
AU2001253621A1 (en) | 2000-04-19 | 2001-11-07 | Schering Corporation | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
AU2001267886A1 (en) | 2000-06-30 | 2002-01-14 | Seikagaku Corporation | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them |
JP2004504356A (ja) | 2000-07-20 | 2004-02-12 | メルク エンド カムパニー インコーポレーテッド | C型肝炎ウイルスのプロセシングおよび複製の抑制 |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
CZ303213B6 (cs) | 2000-07-21 | 2012-05-23 | Schering Corporation | Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek |
AU2001277967A1 (en) * | 2000-07-21 | 2002-02-05 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
CA2410682A1 (en) | 2000-07-21 | 2002-01-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
AR034127A1 (es) * | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6939692B2 (en) | 2000-09-12 | 2005-09-06 | Degussa Ag | Nucleotide sequences coding for the pknB gene |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
MXPA03004299A (es) | 2000-11-20 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de tripeptido de hepatitis c. |
IL155842A0 (en) * | 2000-12-12 | 2003-12-23 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
AU2002230764A1 (en) * | 2000-12-13 | 2002-06-24 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
US6653295B2 (en) * | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
CA2434386C (en) * | 2001-01-22 | 2006-12-05 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2002061149A2 (en) | 2001-01-30 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | A quantitative assay for nucleic acids |
GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
MXPA03008882A (es) | 2001-03-27 | 2003-12-08 | Vertex Pharma | Composiciones y metodos utiles para la infeccion por hcv. |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
JP2005500322A (ja) * | 2001-07-03 | 2005-01-06 | アルタナ ファルマ アクチエンゲゼルシャフト | 3−フェニルイソセリンの製法 |
CN100402549C (zh) | 2001-07-11 | 2008-07-16 | 沃泰克斯药物股份有限公司 | 桥连二环的丝氨酸蛋白酶抑制剂 |
JP2003055389A (ja) | 2001-08-09 | 2003-02-26 | Univ Tokyo | 錯体及びそれを用いたエポキシドの製法 |
US6824769B2 (en) | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
NZ531681A (en) | 2001-10-24 | 2007-05-31 | Vertex Pharma | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
HUP0501067A2 (en) * | 2001-11-14 | 2006-02-28 | Teva Pharma | Amorphous and crystalline forms of losartan potassium and process for their preparation |
ATE443703T1 (de) | 2002-01-23 | 2009-10-15 | Schering Corp | Prolinderivate als ns3-serine protease hemmer, zur verwendung bei der bekämpfung von hepatitis c virusinfektion |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CN100381440C (zh) | 2002-04-11 | 2008-04-16 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂 |
ES2361011T3 (es) | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
KR20050040912A (ko) * | 2002-08-01 | 2005-05-03 | 파마셋 인코포레이티드 | 플라비비리다에 감염 치료용의 비사이클로[4.2.1]노난시스템을 가지는 화합물 |
AU2003277891A1 (en) | 2002-09-23 | 2004-04-08 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
US20040138109A1 (en) | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
CA2413705A1 (en) * | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EP1590442A4 (en) | 2003-02-07 | 2007-07-18 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
JP2006517960A (ja) | 2003-02-18 | 2006-08-03 | ファイザー インコーポレイテッド | C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法 |
JP4550824B2 (ja) | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎抑制化合物 |
CA2516018C (en) | 2003-03-05 | 2011-08-23 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
KR20060008877A (ko) | 2003-04-10 | 2006-01-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 루테늄 착물 촉매 존재하의 복분해 반응에 의한거대사이클릭 화합물의 제조방법 |
ES2381548T3 (es) | 2003-04-11 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A |
EP1613620A1 (en) | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
PL1615613T3 (pl) | 2003-04-18 | 2010-04-30 | Enanta Pharm Inc | Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C |
PE20050204A1 (es) * | 2003-05-21 | 2005-05-04 | Boehringer Ingelheim Int | Compuestos inhibidores de la hepatitis c |
WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
NZ544789A (en) | 2003-07-18 | 2010-01-29 | Vertex Pharma | Dithia-azaspiro-nonane and decane derivatives as inhibitors of serine proteases |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
EP1664090A2 (en) | 2003-08-26 | 2006-06-07 | Schering Corporation | Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus |
UY28500A1 (es) * | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
US20050120398A1 (en) * | 2003-09-12 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Animal model for HCV infection |
TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US6933760B2 (en) * | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
CA2536182C (en) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
TWI280964B (en) | 2003-09-26 | 2007-05-11 | Schering Corp | Macrocyclic inhibitors of hepatitis C virus NS3 serine protease |
RU2006115558A (ru) | 2003-10-10 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
AR045870A1 (es) * | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
PT1677827E (pt) * | 2003-10-27 | 2009-03-13 | Vertex Pharma | Associações para o tratamento do vhc |
US8187874B2 (en) * | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
EP1678202B1 (en) * | 2003-10-27 | 2012-06-13 | Vertex Pharmaceuticals Incorporated | Hcv ns3-ns4a protease resistance mutants |
ES2330944T3 (es) | 2003-10-28 | 2009-12-17 | Vertex Pharmaceuticals Incorporated | Preparacion de derivados del acido 4,5-dialquil-3-acil-pirrol-2-carboxilico mediante sintesis de tipo fischer-fink y acilacion subsiguiente. |
US20050119318A1 (en) * | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN1902216A (zh) | 2003-11-20 | 2007-01-24 | 先灵公司 | 丙肝病毒ns3蛋白酶的去肽化抑制剂 |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2547787A1 (en) | 2003-12-01 | 2005-06-16 | Vertex Pharmaceuticals Incorporated | Compositions comprising fetal liver cells and methods useful for hcv infection |
WO2005058821A1 (en) | 2003-12-11 | 2005-06-30 | Schering Corporation | Inhibitors of hepatitis c virus ns3/ns4a serine protease |
EP1730167B1 (en) | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
EP1713822B1 (en) | 2004-01-30 | 2010-03-17 | Medivir AB | Hcv ns-3 serine protease inhibitors |
US7683033B2 (en) | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
CN102911161A (zh) | 2004-02-20 | 2013-02-06 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
DE602005015093D1 (de) | 2004-02-27 | 2009-08-06 | Schering Corp | Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
US7173057B2 (en) | 2004-02-27 | 2007-02-06 | Schering Corporation | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus |
US7205330B2 (en) | 2004-02-27 | 2007-04-17 | Schering Corporation | Inhibitors of hepatitis C virus NS3 protease |
DE602005021760D1 (de) | 2004-02-27 | 2010-07-22 | Schering Corp | Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
ATE438622T1 (de) | 2004-02-27 | 2009-08-15 | Schering Corp | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
JP2007525510A (ja) | 2004-02-27 | 2007-09-06 | シェーリング コーポレイション | C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての化合物 |
EP1725548B1 (en) * | 2004-03-12 | 2015-01-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US20050249702A1 (en) | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
WO2005113581A1 (en) | 2004-05-20 | 2005-12-01 | Schering Corporation | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease |
KR101370580B1 (ko) * | 2004-06-08 | 2014-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 약학 조성물 |
WO2006000085A1 (en) | 2004-06-28 | 2006-01-05 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
ATE512971T1 (de) | 2004-07-20 | 2011-07-15 | Boehringer Ingelheim Int | Peptidanaloga als hepatitis c-hemmer |
US7423113B2 (en) * | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
CN101068828A (zh) | 2004-08-27 | 2007-11-07 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物 |
EP1804821A4 (en) | 2004-10-01 | 2009-07-15 | Vertex Pharma | INHIBITION OF HCV NS3-NS4A PROTEASE |
TW201424733A (zh) * | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
EP2402331A1 (en) * | 2005-08-02 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2357170A1 (en) * | 2005-08-19 | 2011-08-17 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
WO2007098270A2 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same |
CA2646229A1 (en) * | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
US20070244334A1 (en) | 2006-03-16 | 2007-10-18 | Tanoury Gerald J | Processes and intermediates for preparing steric compounds |
CN101494979A (zh) | 2006-03-20 | 2009-07-29 | 沃泰克斯药物股份有限公司 | 药物组合物 |
CA2646335A1 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
PT2037887E (pt) * | 2006-05-31 | 2010-12-07 | Vertex Pharma | Formulações orais de libertação controlada de um inibidor da enzima conversora de interleucina-1 beta |
-
2006
- 2006-08-25 AR ARP060103711A patent/AR055395A1/es unknown
- 2006-08-28 WO PCT/US2006/033770 patent/WO2007025307A2/en active Application Filing
- 2006-08-28 EA EA200800670A patent/EA200800670A1/ru unknown
- 2006-08-28 AU AU2006282771A patent/AU2006282771B2/en not_active Ceased
- 2006-08-28 EP EP10176969A patent/EP2364984A1/en not_active Withdrawn
- 2006-08-28 KR KR1020087007149A patent/KR20080041715A/ko not_active Application Discontinuation
- 2006-08-28 CA CA002620621A patent/CA2620621A1/en not_active Abandoned
- 2006-08-28 US US11/511,109 patent/US7985762B2/en not_active Expired - Fee Related
- 2006-08-28 JP JP2008528258A patent/JP5394063B2/ja not_active Expired - Fee Related
- 2006-08-28 NZ NZ566197A patent/NZ566197A/en not_active IP Right Cessation
- 2006-08-28 EP EP06813916A patent/EP1917269B1/en active Active
- 2006-08-28 BR BRPI0615223-6A patent/BRPI0615223A2/pt not_active IP Right Cessation
- 2006-08-28 ES ES06813916T patent/ES2374943T3/es active Active
- 2006-08-28 CN CNA2006800390595A patent/CN101316852A/zh active Pending
- 2006-08-28 AT AT06813916T patent/ATE530554T1/de not_active IP Right Cessation
- 2006-08-28 TW TW095131649A patent/TW200730533A/zh unknown
- 2006-08-28 MX MX2008002606A patent/MX2008002606A/es active IP Right Grant
- 2006-08-28 EP EP10182604.8A patent/EP2366704B1/en not_active Not-in-force
- 2006-08-28 GE GEAP200610581A patent/GEP20115280B/en unknown
-
2008
- 2008-02-21 IL IL189668A patent/IL189668A0/en unknown
- 2008-02-25 ZA ZA200801793A patent/ZA200801793B/xx unknown
- 2008-03-10 EC EC2008008258A patent/ECSP088258A/es unknown
- 2008-03-25 NO NO20081467A patent/NO20081467L/no not_active Application Discontinuation
-
2011
- 2011-02-28 US US13/036,930 patent/US8440706B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2006282771B2 (en) | 2012-08-09 |
AR055395A1 (es) | 2007-08-22 |
ATE530554T1 (de) | 2011-11-15 |
KR20080041715A (ko) | 2008-05-13 |
NO20081467L (no) | 2008-05-15 |
US20070179167A1 (en) | 2007-08-02 |
TW200730533A (en) | 2007-08-16 |
NZ566197A (en) | 2011-07-29 |
US8440706B2 (en) | 2013-05-14 |
ES2374943T3 (es) | 2012-02-23 |
EP1917269B1 (en) | 2011-10-26 |
EP1917269A2 (en) | 2008-05-07 |
AU2006282771A1 (en) | 2007-03-01 |
IL189668A0 (en) | 2008-06-05 |
US7985762B2 (en) | 2011-07-26 |
EP2366704A1 (en) | 2011-09-21 |
EP2366704B1 (en) | 2013-10-23 |
EP2364984A1 (en) | 2011-09-14 |
MX2008002606A (es) | 2008-03-14 |
JP2009506078A (ja) | 2009-02-12 |
CA2620621A1 (en) | 2007-03-01 |
WO2007025307A2 (en) | 2007-03-01 |
EA200800670A1 (ru) | 2009-12-30 |
JP5394063B2 (ja) | 2014-01-22 |
ECSP088258A (es) | 2008-06-30 |
WO2007025307A3 (en) | 2007-04-26 |
CN101316852A (zh) | 2008-12-03 |
GEP20115280B (en) | 2011-09-12 |
US20110165120A1 (en) | 2011-07-07 |
ZA200801793B (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0615223A2 (pt) | inibidores das serina proteases | |
MX2009009174A (es) | Inhibidores de serina-proteasas para el tratamiento de infecciones por el virus de hepatitis c. | |
RS52534B (en) | MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS | |
BRPI0615029A2 (pt) | processos e intermediários | |
ATE513844T1 (de) | Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus | |
ES2240446T3 (es) | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. | |
DE602005015834D1 (de) | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus | |
MY145081A (en) | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | |
BRPI0416902A (pt) | inibidores de ns3/ns4a serina protease do vìrus da hepatite c | |
NO20064357L (no) | Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease | |
TW200602037A (en) | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | |
EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
EA200800371A1 (ru) | Ингибиторы ns3 протеазы вгс | |
WO2008057995A3 (en) | Hcv protease inhibitors | |
MX2009011064A (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
DE502005008057D1 (de) | Substituierte cyclopenten-verbindungen | |
CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
MX2009008925A (es) | Compuestos de la formula (i) como inhibidores de proteasa de serina. | |
NO20074544L (no) | Inhibering av HER2-losriving med matriksmetalloproteaseantagonister | |
DE602005010421D1 (de) | Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen | |
MX2010004704A (es) | Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c. | |
EA200970372A1 (ru) | Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение | |
UA90909C2 (en) | Hcv ns3 protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014. |